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Introduction: Tuberculosis continues to be a public health priority. Indigenous peoples are 
vulnerable groups with cultural determinants that increase the risk of the disease.
Objective: To determine molecular epidemiology and phenotypical features and of 
Mycobacterium tuberculosis isolates from indigenous people in Colombia during the period 
from 2009 to 2014.
Materials and methods: We conducted an analytical observational study; we analyzed 
234 isolates to determine their patterns of sensitivity to antituberculosis drugs and their 
molecular structures by spoligotyping.
Results: The isolates came from 41 indigenous groups, predominantly the Wayúu (13.10%) 
and Emberá Chamí (11.35%). We found 102 spoligotypes distributed among seven genetic 
families (37.2% LAM, 15.8% Haarlem, 8.1% T, 3.4% U, 2.6% S, 2.1% X, and 0.9%, Beijing). 
The association analysis showed that the non-clustered isolates were related to prior 
treatment, relapse, orphan spoligotypes, and the Beijing family. The H family presented an 
association with the Arhuaco and Camëntŝá indigenous groups, the U family was associated 
with the Wounaan group, and the T family was associated with the Motilón Barí group.
Conclusions: This is the first national study on M. tuberculosis characterization in 
indigenous groups. The study evidenced that diagnosis in indigenous people is late. We 
described 53% of orphan patterns that could be typical of the Colombian indigenous 
population. The high percentage of grouping by spoligotyping (62%) could indicate cases 
of active transmission, a situation that should be corroborated using a second genotyping 
marker. A new Beijing spoligotype (Beijing-like SIT 406) was identified in Colombia.
Keywords: Tuberculosis/epidemiology; indigenous population (public health); genotype; 
molecular epidemiology; drug resistance.
Caracterización de aislamientos clínicos de Mycobacterium tuberculosis de pueblos 
indígenas de Colombia
Introducción. La tuberculosis es prioridad de salud pública. Los pueblos indígenas son 
vulnerables debido a los factores culturales determinantes que aumentan el riesgo de 
tuberculosis.
Objetivo. Determinar la epidemiologia molecular y las características fenotípicas de los 
aislamientos de Mycobacterium tuberculosis de pueblos indígenas de Colombia entre 2009 y 2014.
Materiales y métodos. Se hizo un estudio observacional analítico; se analizaron 234 
aislamientos para determinar la sensibilidad a los fármacos antituberculosos y la estructura 
molecular usando spoligotyping. La información epidemiológica se recolectó utilizando el 
formato único de vigilancia de micobacterias.
Resultados. Los aislamientos provenían de 41 grupos indígenas, principalmente los wayúu 
(13,10 %) y emberá chamí (11,35 %). Se encontraron 102 genotipos distribuidos en siete 
familias genéticas (37,2 %, LAM; 15,8 %, Haarlem; 8,1 %, T; 3,4 %, U; 2,6 %, S; 2,1 %, 
X, y 0,9%, Beijing). El análisis de asociación mostró que los aislamientos no agrupados 
se asociaron con el tratamiento previo, las recaídas, los genotipos huérfanos y la familia 
Beijing. La familia H presentó una asociación con los grupos indígenas arhuaco y camëntŝá, 
la familia U se asoció con el grupo wounaan y la familia T con el grupo motilón barí.
Conclusiones. Este es el primer estudio nacional de caracterización de M. tuberculosis 
en grupos indígenas. Se evidenció que el diagnóstico en indígenas es tardío, y que 53 % 
de los patrones huérfanos podrían ser típicos de la población indígena colombiana. El alto 
porcentaje de agrupamiento por spoligotyping (62%) podría indicar casos de transmisión 
activa, una situación que debe ser corroborada usando un segundo marcador de 
genotipificación. Se identificó un nuevo genotipo (Beijing-like SIT 406) en Colombia.
Palabras clave: Tuberculosis/epidemiología; población indígena; genotipo; epidemiología 
molecular; resistencia a medicamentos.
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Tuberculosis continues to be a public health priority worldwide and its 
control is part of the sustainable development goals established by the United 
Nations organization (1). The World Health Organization (WHO) estimated 
that 10.4 million new tuberculosis cases would occur in 2016 (2); in Colombia, 
13,871 new tuberculosis cases were registered that same year, of which 840 
occurred among indigenous populations (3).
The global “End Tuberculosis Strategy” adopted by WHO as a work 
approach for member states seeks to provide continuity for tuberculosis 
control actions after 2015. The strategy considers the protection and 
promotion of ethics and equity in its principles and fosters differential attention 
to vulnerable populations including indigenous groups (4). The social and 
cultural determinants and the immunological factors typical of indigenous 
peoples are associated with a predisposition for the disease. Risk factors 
such as overcrowding, malnutrition, and difficulties in accessing healthcare 
services are linked primarily to the geographic areas that these people 
inhabit. Additionally, ignorance of the disease has been described (5-7).
According to the Organización Nacional de Indígenas Colombianos, there 
are 102 indigenous groups in Colombia (8). However, the last national census 
carried out by the Departamento Administrativo Nacional de Estadística 
(DANE) registered only 87 indigenous groups; these groups are distributed in 
710 reservations located in 27 of the 36 territorial entities of the country (9).
Several studies worldwide have shown high rates of tuberculosis among 
indigenous peoples, mainly associated with difficulties for accessing health 
services. The active transmission of Mycobacterium tuberculosis has also been 
confirmed through molecular epidemiology studies (10-15). The approach 
outlined in the strategic plan “Colombia libre de tuberculosis, 2010-2015” by 
the Ministry of Health and Social Protection prioritizes vulnerable populations 
and favors the recognition of the actual tuberculosis situation in these peoples. 
The following incidence rates have been reported: More than 200 cases per 
100,000 inhabitants for the departments of Cesar and Antioquia, more than 
80 cases per 100,000 inhabitants in Nariño and La Guajira, and more than 30 
cases per 100,000 inhabitants in Guaviare and Guainía (16,17). These rates 
are well above the national incidence, which has been approximately 25 cases 
per 100,000 inhabitants over the last ten years (3).
Classical epidemiology has contributed with important advances in the 
understanding of the determinants associated with the development of 
tuberculosis. However, during the last few decades, the use of techniques 
such as spoligotyping and the implementation of molecular epidemiology 
have strengthened the study of infectious diseases. At present, associations 
can be determined between genotypes and the manifestation of multidrug 
resistance, defined as joint resistance to isoniazid and rifampicin (2). These 
approaches provide accurate information and increase our understanding of 
the transmission dynamics of pathologies with a public health impact such as 
tuberculosis (18).
The objectives of this study were to determine molecular epidemiology and 
phenotypical features of M. tuberculosis isolates from indigenous people in 
Colombia between 2009 and 2014.
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Materials and methods
Epidemiological information
The information (origin of indigenous people, gender, age, occupational 
profile, possible risk factors, and clinical characterization of tuberculosis) was 
compiled in an Excel 2013 database. This information was based on 234 
unique mycobacterial surveillance forms submitted to the Colombian Instituto 
Nacional de Salud Mycobacteria Group during the 2009-2014 period by the 
health secretariats in each department.
These records corresponded to 229 individuals from indigenous groups 
diagnosed with tuberculosis. Five people contributed two isolates of M. 
tuberculosis at different times. In some cases, the tuberculosis and HIV 
databases of the Sistema Nacional de Vigilancia en Salud Pública, Sivigila, 
were consulted to complement the information.
Clinical isolates
A total of 234 M. tuberculosis clinical isolates from indigenous people 
diagnosed with tuberculosis between 2009 and 2014 were obtained from 
the biobank of the Instituto Nacional de Salud Mycobacteria Group. The 
cryopreserved isolates were recovered in Löwenstein-Jensen solid medium 
and incubated at 37°C for two to four weeks to obtain bacillary biomass.
Identification of species and drug susceptibility test 
Species identification was performed using the immunochromatography 
test (TB Ag MPT64 Rapid, Cat N° 08FK50), which detected the MPT64 
protein and was confirmed by spoligotyping. First and second-line drug 
sensitivity tests were performed using the automated BACTEC MGIT TM 
960™ system according to the conditions previously standardized by the 
Instituto Nacional de Salud Mycobacteria Group. 
First-line drug sensitivity tests were performed as follows: 1 μg/
ml of rifampicin (R), 0.1 and 0.4 μg/ml of isoniazid (H), 1 and 4 μg/ml of 
streptomycin (S), and 1 and 7.5 μg/ml of ethambutol (E). In cases with 
resistance to H and/or R, the tests were performed as follows: 2.5 μg/ml of 
kanamycin (Km), 1 μg/ml of amikacin (Am), 2.5 μg/ml of capreomycin (CM), 
and 2 μg/ml of ofloxacin (Ofx). 
The interpretation was done using the EpiCenter and TB-eXiST software™ 
(Becton Dickinson 2009, Springer 2009). The internal quality control of these 
tests was performed using American Type Culture Collection (ATCC) reference 
strains and the external control supplied by the Laboratorio Supranacional de 
Referencia at the Chilean Instituto de Salud Pública de Chile.
Spoligotyping
The DNA extraction process was performed according to van Soolingen, et 
al. (19). The spoligotyping analysis was performed according to Kamerbeek, 
et al. (20). The polymerase chain reaction (PCR) product was hybridized 
on a commercial membrane (Isogen-LifeScience, The Netherlands). The 
hybridization results were visualized by chemiluminescence using the ECL 
Direct™ commercial kit (Amersham, UK) and developed by exposure to a 
photosensitive film. DNA from the M. tuberculosis H37Rv and M. bovis BCG 
P3 reference strains were used as a positive control.
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Spoligotyping results were converted into binary and octal codes for 
the determination of the genetic family and the corresponding Spoligotype 
International Type (SIT) code using the SpolDB4 international database of 
the Institute Pasteur de la Guadeloupe (Pasteur Institute of Guadeloupe) 
(21). The database of the Colombian INS and previous genotyping studies 
conducted in the country were also consulted for comparisons with circulating 
spoligotypes (22-27). We calculated the Hunter and Gaston index to 
determine the discriminating power of spoligotyping (28).
Statistical analysis
We conducted a percentage description of the analyzed variables, as 
well as a bivariate statistical analysis to determine the possible associations 
between the sociodemographic variables, the sensitivity patterns for 
antituberculosis drugs, and the spoligotypes and clusters obtained by 
spoligotyping. We used the chi-square test or the Fisher’s exact test with 
a 95% confidence interval and a significance of 0.05 using the statistical 
package Epi Info 7.0TM. The analyses were performed for 234 clinical isolates.
Ethical considerations
All study procedures were approved by the INS Research Ethics 
Committee. According to the Resolution 8430, 1993, issued by the Colombian 
Ministry of Health, this study did not require informed consent as all of 
the samples used were isolates obtained from the biobank of the INS 
Mycobacteria Group and no personal information from patients was extracted 
(i.e., they were anonymous samples).
Results
Sociodemographic characteristics of the indigenous populations
We analyzed isolates from 41 indigenous groups, predominately from the Wayúu 
(n=30, 13.10%), the Emberá Chamí (n=26, 11.35%), the Awá (n=18, 7.86%), the 
Nasa Páez (n=15, 6.55%), and the U’wa (n=12, 5.24%) (tables 1 and 2).
The gender distribution showed that 51.09% (n=117) of the study population 
was male and 48.91% (n=112) was female. The age ranged from three months 
to 100 years. The age subgroups were 0 to 4 years, 5.68% (n=13); 5 to 14 
years, 5.68% (n=13); 15 to 29 years, 29.7% (n=68); 30 to 44 years, 25.8% 
(n=59); 45 to 59 years, 16.59% (n=38), and 60 years or over, 16.59% (n=38).
 Occupational profile and possible risk factors
The most frequent occupations were homemaker (n=63, 27.51%) and 
farmer (n=50, 21.83%). Other occupations, such as artisan, shaman, botanist, 
and rancher, were less frequent. The possible risk conditions associated with 
the development of tuberculosis are described in table 3.
Clinical and phenotypical characterization of the isolates
Pulmonary tuberculosis was present in 96.94% (n=222) of the cases, whereas 
extrapulmonary tuberculosis was present in only 3.06% (n=7) of the cases; 
83.84% (n=192) of the individuals were classified as new cases, 10.91% (n=25) 
were previously treated, and 5.24% (n=12) had no recorded data available. Of 
the previously treated cases, 32% (n=8) were relapses, 8% (n=2) were failures, 
and 60% (n=15) were cases in which a category could not be established. Three 
people (1.31%) were recorded as deceased due to tuberculosis.
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Indigenous people n % Indigenous people n %
Wayúu
Emberá ChamÍ
Awá
Nasa Páez
U’wa
Arhuaco
Motilón Barí
Wounaan
Emberá Katío
Tikuna
Guahibo
Nukak Makú
Emberá
Inga
Sikuani
Tucano
Camëntŝá
Cubeo
Guayabero
Kogui
Panare
30
26
18
15
12
8
8
8
7
6
5
4
4
4
4
4
3
3
3
3
3
13.10
11.35
7.86
6.55
5.24
3.49
3.49
3.49
3.06
2.62
2.18
1.75
1.75
1.75
1.75
1.75
1.31
1.31
1.31
1.31
1.31
Yukpa
Zenú
Amorúa
Hitnu
Kogui-Malayo-Arhuaco
Pastos
Siona
Cocama
Desano
Ennaka
Guambiano
Guanano
Kankuamo
Misak
Mokana
Piapoco
Puinave
Quillacinga
Yagua
Yuco
ND
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
22
1.31
1.31
0.87
0.87
0.87
0.87
0.87
0.44
0.44
0.44
0.44
0.44
0.44
0.44
0.44
0.44
0.44
0.44
0.44
0.44
9.61
Table 1. Indigenous groups identified and number of persons who contributed isolates (n=229; 100%)
ND: No data
Departament Indigenous settlement n Total %
Amazonas ND
Tikuna
Cocama
Yagua
5
5
1
1
12 5,2
Antioquia Emberá Katío 1 1 0,4
Arauca Guahibo
Hitnu
ND
Sikuani
U’wa
Piapoco
2
2
2
1
1
1
9 3,9
Atlántico Mokana 1 1 0,4
Boyacá U wa 7 7 3,1
Caldas Emberá chamÍ
Tikuna
2
1
3 1,3
Casanare Amorúa 2 2 0,9
Cauca Nasa Páez
Guambiano
Misak
11
1
1
13 5,7
Cesar Arhuaco
Wayúu
Kankuamo
ND
Yuco
Yukpa
7
2
1
2
1
3
16        7
Chocó Emberá
Emberá chamÍ
Emberá Katío
3
2
1
6 2,6
Table 2. Distribution of indigenous groups per department
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Córdoba Emberá Katío
Zenú
3
3
6 2,6
Cundinamarca Emberá 1 1 0,4
Guainía ND
Puinave
3
1
4 1,7
Guaviare Nukak Makú
Guayabero
Panare
Tucano
4
3
3
2
12 5,2
Huila Nasa Páez 2 2 0,9
La Guajira Wayúu 28 28 12,2
Magdalena Kogui
Kogui-Malayo- Arhuaco
Arhuaco
Ennaka
3
2
1
1
7 3,1
Meta ND
Sikuani
Nasa Páez
5
3
1
9 3,9
Nariño Awá
Pastos
Inga
Quillacinga
ND
18
2
1
1
1
23      10
Norte de Santander Motilon Barí
U’wa
5
3
8 3,5
Putumayo Camëntŝá
Inga
ND
Siona
3
2
1
2
8 3,5
Quindío Emberá chamÍ 5 5 2,2
Risaralda Emberá chamÍ
ND
17
2
19 8,3
Santander Motilon Barí
U wa
Inga
3
1
1
5 2,2
Valle del Cauca Wounaan
ND
Emberá chamÍ
Nasa Páez
8
2
1
1
12 5,2
Vaupés Cubeo
Tucano
Desano
Guanano
3
2
1
1
7 3,1
Vichada Guahibo 3 3 1,3
Total 229 229 100
ND: No data
*Two pregnant individuals and one individual with chronic obstructive pulmonary disease
** 96 (41.7%) were HIV-negative and 127 (55.5%) had no data on HIV status.
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The 234 positive cultures were recovered from the following clinical samples: 
Sputum, 82.1% (n=192); gastric aspirate, 7.7% (n=18); secretion with no origin 
identified, 3% (n=7); biopsy lymph node, 2.1% (n=5); bronchoalveolar lavage, 1.7% 
(n=4); cerebrospinal fluid, 0.9% (n=2), and ascitic fluid, peritoneal fluid, and pleural 
fluid, 1.3% (n=3). No information was recorded for 1.3% (n=3) of the samples.
 Bacilloscopy 
A total of 26.5% (n=62) of the cases were positive in the bacilloscopy 
(BK+), 23.5% (n=55) were BK++, and 19.2% (n=46) were BK+++, of which 
15.2% (n=7) corresponded to minors (3 to 14 years old). The negative BK 
samples corresponded to 19.2% (n=45) of the cases, and no information was 
recorded for 11.1% (n=26) of the samples.
All clinical samples had a positive culture on the Löwenstein-Jensen solid 
medium. Mycobacterium tuberculosis complex identification was positive in 
all cases.
Drug resistance test
Of the 234 isolates received, five people contributed two isolates at 
different times. Only one isolate from each of these cases was considered for 
the sensitivity profiles.
In total, 192 cases were classified as new cases. Of these, sensitivity 
test results were obtained for 98.44% (n=189); 91% (n=172) of them were 
sensitive to all the tested first-line drugs, and 8.9% (n=17) presented 
resistance to at least one of the drugs tested. Of the 189 isolates analyzed, 
3.17% (n=6) were multidrug resistant. Of the previously treated cases (n=25), 
64% (n=16) were sensitive to all tested first-line drugs and 36% (n=9) were 
resistant to at least one drug tested. Of the 25 isolates analyzed, 12% (n=3) 
was multidrug resistant. Of the cases without classification based on a 
previous history of treatment (n=12), 91.66% (n=11) were sensitive to all first-
line drugs, and the remaining case was multidrug resistant (8.33%). 
The multidrug resistant isolates came from the indigenous groups Emberá 
Chamí (n=3), Emberá (n=3), Awá (n=1) and the samples without data (n=2). 
All cases that showed resistance to H and/or R were also evaluated with 
second-line drugs, although none presented resistance.
Spoligotyping
All isolates included in the study (n=234) were confirmed as M. 
tuberculosis by spoligotyping. No circulation of other members of the M. 
tuberculosis complex was detected; 164 isolates were distributed in seven 
Risk factor    n   % Vulnerable condition    n   %
Malnutrition*
Pregnancy
Diabetes
HIV-positive**
Drug dependence
ND
Total
28
6
1
6
1
187
229
12.2
2.6
0.4
2.6
0.4
81.8
Schoolchildren
Displaced
Homeless
Border population
ND
Total
18
13
1
14
183
229
7.9
5.7
0.4
6.1
79.9
Table 3. Risk factors for tuberculosis identified in the study population
ND: No data
*Two pregnant individuals and one individual with chronic obstructive pulmonary disease
** 96 (41.7%) were HIV-negative and 127 (55.5%) had no data on HIV status.
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genetic families: Latin American-Mediterranean (LAM, 37.2%, n=87), Haarlem 
(H, 15.8%, n=37), T (8.1%, n=19), U (3.4%, n=8), S (2.6%, n=6), X (2.1%, 
n=5), and Beijing (0.9%, n=2); a total of 29.9% of the isolates showed orphan 
spoligotype patterns for genetic families (n=70).
Out of 234 isolates, 102 spoligotypes were identified, of which 47.1% 
(n=48) were previously described in the SpolDB4 database (table 4) and 
52.9% (n=54) were orphan spoligotypes (Supplementary table 1).
Family SIT n % Family SIT n     %
Orphans* 
LAM9
LAM2
Harleem1
Harleem3
T1
LAM5
U (LAM3?)
LAM4
S
T2
LAM2**
LAM9
Harleem1
Harleem1
Harleem2
LAM1
LAM2-LAM4
LAM9
LAM9
LAM9
T2**
X1
X3
Beijing-like
NA
42
17
62
50
53
93
106
60
34
118
1691
162
47
727
2
20
194
150
1535
1933
52
217
91
190
70
33
18
14
13
8
7
6
4
4
4
3
3
2
2
2
2
2
2
2
2
2
2
2
1
29.9
14.1
7.7
6.0
5.6
3.4
3.0
2.6
1.7
1.7
1.7
1.3
1.3
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.4
Beijing-like**
H1
H3
H3**
H3**
LAM2
LAM2
LAM3
LAM3
LAM6**
LAM9
LAM9
LAM9**
LAM9**
S**
S**
T1**
T1**
T1 (Tv)**
T2
T2
U
U**
X2
406
610
75
418
615
172
1661
33
130
1768
388
509
1074
1530
1253
1938
278
628
159
848
1355
160
1451
137
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
Table 4. Distribution of the spoligotypes found in the isolates characterized by spoligotyping 
(n=234; 100%)
Tv: Tuscany variant; SIT: Spoligotype International Type
*Orphan spoligotypes are described in Appendix 3. 
** Spoligotypes reported for the first time in Colombia
Out of the spoligotypes described in the study, 62% (n=144) had not been 
reported in previous genotyping studies in Colombia; the spoligotype Beijing-
like SIT 406 was of particular interest.
When we compared the proportion of spoligotypes found with the INS 
database and the information reported in Colombia, we established that the 
spoligotypes with the greatest circulation among the indigenous population 
were LAM 9 SIT42, H1 SIT62, H3 SIT50, T1 SIT53, and H1 SIT727.
Clustering by spoligotyping and variable association analysis
The similarity dendrogram showed the presence of 30 clusters consisting 
of two to 37 isolates for a total of 162 isolates, while 72 isolates were not 
clustered (Supplementary figure 1).
Non-clustered isolates were associated with being a previously treated 
patient (p=0.011), relapse (p=0.039), orphan spoligotypes (p=<0.001), and 
belonging to the Beijing family (p=0.014) (table 5).
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Table 5. Bivariate analyses of sociodemographic variables and genetic families identified by 
spoligotyping
Table 6. Bivariate analysis of genetic families identified by spoligotyping with first-line drug 
resistance
PT: Previously treated; ND: No data; Ref: Reference value
* Fisher’s exact test
** Chi-squared test; confidence level: 95 %
* Fisher’s exact test, confidence level: 95 %
Variables
Clustering
Total p*Yes No
n %     n %
Gender Male
Female
84
78
  70
68.4
36
36
30
31.6
120
114
Ref
  0.794**
Age (years) 0 to 4
5 to 14
15 to 44
45 to 59
≥60
11
11
93
23
24
73.3
84.6
72.1
  59
63.2
4
2
36
16
14
26.7
15.4
27.9
 41
36.8
15
13
129
39
38
  1,000*
  0.514*
Ref
  0.120**
  0.290**
Treatment New
PT
Relapse
Failure
Deceased
ND
140
7
3
2
2
8
73.7
43.8
37.5
66.7
66.7
57.1
50
9
5
1
1
6
26.3
56.2
62.5
33.3
33.3
42.9
190
16
8
3
3
14
Ref
  0.011**
  0.039*
  1,000*
  1,000*
  0.181**
MDR Yes
No
8
154
66.7
69.4
4
68
33.3
30.6
12
222
  1,000*
Ref
Genetic families LAM
H
T
U
S
X
Beijing
Orphans
78
33
14
6
4
4
0
23
89.7
89.2
73.7
  75
66.7
  80
    0
32.9
9
4
5
2
2
1
2
47
10.3
10,821
26.3
25
33.3
20
100
67.1
87
37
19
8
6
5
2
70
Ref
  1,000*
  0.126**
  0.231*
  0.147*
  0.445*
  0.014*
<0.001**
Family
Susceptibility pattern
Total p*Resistant Sensitive
    n   %    n   %
Orphans 
T
LAM
Haarlem
X
Beijing 
U
S
7
6
3
2
2
1
1
0
10
31.6
3.5
5.4
40
50
12.5
0
63
13
84
35
3
1
7
6
90
68.4
96.6
94.6
60
50
87.5
100
70
19
87
37
5
2
8
6
0.111
0.018
Ref
0.634
0.022
0.088
0.301
1.000
The analysis showed an association between the T family (p=0.018) 
and the X family (p=0.022) for resistance to antituberculosis drugs (table 6). 
Conversely, an association was detected between the failure of treatment 
(p=0.005) and the presence of multidrug resistance. The S (p=0.010) and X 
families (p=0.007) were associated with multidrug resistance. No significant 
association was found between belonging to a particular indigenous group 
and drug resistance (table 7).
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The association of the H family was significant for the Arhuaco (p=0.012) 
and Camëntŝá (p=0.033) indigenous groups. The U family was associated 
with the Wounaan (p=0.014) group, and the T family was associated with the 
Motilón Barí (p=0.002) group (data not presented).
Discussion
Indigenous peoples are among the vulnerable groups defined by the WHO 
and the Colombian Programa Nacional de Control de Tuberculosis and they 
are one of the population groups with the highest morbidity and mortality rates 
associated with tuberculosis (16). According to Cardona, et al. (6), some of 
the factors associated with this vulnerability involve inherent characteristics of 
these populations, such as their nomadic condition, their settlement in rural 
areas that hinders timely access to medical services, and the low adherence 
to the antituberculosis treatment observed in these population groups.
The number of tuberculosis cases recorded in this study represented 
5.6% of the total tuberculosis cases in the indigenous population of Colombia 
according to the Sivigila reports from 2009 to 2014 (n=4,205). In the country, 
especially in indigenous areas, the most accessible diagnostic method is 
bacilloscopy (89.5% of tuberculosis cases for 2015) (3) instead of culture. 
The clinical isolates in this study were recovered from these cultures for the 
characterization of drug sensitivity and molecular epidemiology analyses. 
Table 7. Bivariate analyses of variables associated with multidrug resistance
PT: Previously treated; ND: No data; Ref: Reference value
* Fisher’s exact test; 
** Chi-squared test, confidence level: 95 %
Variables
Multidrug resistance
Total p*Yes No
  n %  n %
Gender Male
Female
6
6
  5
  5.3
114
108
95
94.7
120
114
Ref
0.927**
Age (years) 0 to 4
5 to 14
15 to 44
45 to 59
≥60
1
0
6
3
2
  6.7
  0
  4.7
  7.7
  5.3
14
13
123
36
36
93.3
100
95.3
92.3
94.7
15
13
129
39
38
0.545*
1,000*
Ref
0.435**
1,000**
Treatment New
PT
Relapse
Failure
Deceased
ND
7
1
1
2
1
0
  3.68
  6.25
12.5
66.67
33.33
  0
183
15
7
1
2
14
96.32
93.75
87.5
33.33
66.67
100
190
16
8
3
3
14
Ref
0.482*
0.285*
0.005*
0.120*
1,000*
Genetic families LAM
H
T
U
S
X
Beijing
Orphans
1
1
2
1
2
2
1
2
  1.15
  2.70
10.53
12.5
33.3
40
50
  2.9
86
36
17
7
4
3
1
68
98.85
97.30
89.47
87.5
66.7
60
50
97.1
87
37
19
8
6
5
2
70
Ref
0.509*
0.082*
0.162*
0.010*
0.007*
0.447*
0.586*
Indigenous groups Emberá Chamí
Emberá
Awá
Camëntŝá
Wounaan
7
2
1
1
1
25
50
  5.6
33.3
12.5
21
2
17
2
7
75
50
94.4
66.7
87.5
28
4
18
3
8
Ref
0.557*
0.124*
1.000*
0.651*
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A progressive increase of more than 13.4-fold was observed in the number 
of cultures sent to the INS from indigenous communities between 2009 and 
2014 (2009, n=7, and 2014, n=94). This increase was made possible by the 
implementation of memo 058 of 2009 (29) and the subsequent publication 
of the strategic plan “Colombia Free of Tuberculosis, 2010-2015” (30), which 
established actions against tuberculosis among indigenous peoples. However, 
the country must strengthen the dissemination of public policies and ensure its 
compliance. In this case, all respiratory symptomatic individuals belonging to 
indigenous peoples should undergo more sensitive laboratory tests, such as 
those based on DNA amplification, culture, and drug sensitivity tests.
Regarding the presence of tuberculosis cases among indigenous groups, 
the highest number was registered among the Wayúu people whose groups 
inhabit La Guajira peninsula and share territory with Venezuela, which means 
there is a continuous passage between the reservations of both countries. 
In addition to the geographical conditions of the area, other conditions such 
as the lack of permanent access to drinking water supply contribute to 
malnutrition and, therefore, to infectious diseases (31,32).
The indigenous group with the second highest number of tuberculosis 
cases was the Emberá Chamí, which is primarily located in the Colombian 
coffee-growing region, whose beliefs about the disease have a spiritual origin 
and where transmission occurs by settlers. In such a context, the treatment 
is dictated by the shamans. Although the group also resorts to modern 
medicine, this approach could explain why this area is the second most 
affected by the disease (17).
The indigenous group with the third highest number of tuberculosis cases 
was the Awá. This Amerindian group living in the border between Colombia 
and Ecuador is one of the most vulnerable populations in Colombia (16). 
Their main settlements are located in the municipalities of Ricaurte, Tumaco, 
and Barbacoas in the department of Nariño. Little is known about their 
traditions because they do not allow their culture to be known. Glyphosate 
fumigations and invasion of their lands by illegal armed groups may have 
resulted in poverty, shortage of foods of animal origin, and low soil fertility, 
which have impacted their health conditions (31-33).
The number of tuberculosis cases was similar in women and men 
contrasting with global reports in which men were the most affected by the 
disease (2). This difference may be related to deficiencies in the treatment 
of index cases, late diagnosis, and social factors such as "machismo", as in 
these groups men decide whether women can go to health care centers when 
they are sick (34), as well as to women’s low education level hindering them 
from participating in decision-making, thus making access to diagnosis and 
timely care difficult (35), and child care, which also limits women’s access to 
healthcare services. This situation calls for reinforcing prevention, diagnosis, 
monitoring, and control programs in families to prevent transmission, 
especially from mothers affected by the disease to underage children.
Regarding age, the group most affected by tuberculosis was between 15 and 
29 years. The younger and older age groups had fewer cases. This situation 
coincided with previous studies conducted by Culqui, et al., whose study on 
tuberculosis among indigenous peoples from Perú reported that 78.6% of the 
cases occurred in people of productive age (adolescents and adults), 2.5% 
in children and infants, and 7% in older adults (12). This distribution may be 
explained by the displacement that indigenous peoples in productive age are 
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forced to for food or resources, which means they have contact with non-
indigenous people and, therefore, with different types of diseases (36).
As regards bacilloscopy, 42.7% of the individuals had ≥++ results 
indicating a late diagnosis, which can reflect health care access difficulties 
and answer to the dispersion of communities and the lack of knowledge 
about the disease among other factors (31). Studies conducted by Ribeiro, 
et al., and Gaviria, et al., (37,38) found a relation between late tuberculosis 
diagnosis and disease-associated social stigma, as well as insufficient 
knowledge of health professionals regarding the identification of respiratory 
symptoms in a timely manner.
The proportion of multidrug resistant isolates cannot be compared with that 
found worldwide or in national annual reports. According to WHO (2), multidrug 
resistance is expected in 3.3% of new cases. In 2007 in Colombia, 3.2% of 
new tuberculosis cases in the general population were multidrug resistant 
tuberculosis while in tuberculosis previously treated cases it was 20%. Any 
number of cases is indicative of the failure of treatment, the transmission 
of primary drug-resistant strains, and lack of adherence and follow-up. 
The presence of resistant isolates in a vulnerable population such as the 
indigenous populations should prompt the implementation of programmatic 
actions to control tuberculosis sensitivity and develop shorter, less toxic, and 
more effective treatment regimens to avoid second-line treatments. 
Since tuberculosis control and eradication are closely linked to the 
knowledge about the disease, the social, cultural, economic, and biological 
aspects contributing to the persistence of the bacillus in the community must 
be elucidated. In this setting, molecular epidemiology has positioned itself 
as a useful tool for the study of transmission dynamics by implementing 
techniques such as spoligotyping (39).
In this study, the genetic families most frequently found by spoligotyping 
among indigenous peoples were in descendent order LAM, Haarlem, and T, a 
finding consistent with previous reports for the Colombian population (22-27). 
However, the high number of orphan spoligotypes recorded is of particular 
interest for public health. Another important consideration is the presence 
in the municipality of Buenaventura of the Beijing family due to its virulence, 
strong association with multidrug resistance, and extensive drug resistance 
(24,26,27,40-42). 
Buenaventura is the most important port in Colombia and probably it was 
the gateway of this genotype from Asia into the country. Our results confirmed 
a new Beijing spoligotype (Beijing-like SIT 406) circulating in Colombia; this 
is the second report of this spoligotype in Latin America (43). The specific 
location was Tumaco.
The 14 spoligotypes we identified by spoligotyping that had not been 
previously reported in Colombia were the following: [LAM2 SIT 1691, T2 SIT 52, 
H3 SIT 418, H3 SIT 615, LAM 6 SIT 1768, LAM9 SIT 1074, LAM9 SIT 1530, 
S SIT 1253, S SIT 1938, T1 SIT 278, T1 SIT 628, T1 (Tuscany variant) SIT 
159, U SIT 1451, and Beijing-like SIT 406], as well as 51 orphan spoligotypes 
without prior descriptions in the international SpolDB4 database nor in national 
studies (22-27). These spoligotypes could be circulating exclusively among the 
indigenous populations, which calls for more in-depth studies. Only three of the 
orphan patterns identified in the indigenous Risaralda and Putumayo groups 
had previously been described in Colombia circulating in the departments of 
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Putumayo, Cauca, and in Bogotá (23-24). The presence of these spoligotypes 
among indigenous populations most likely responds to social factors such 
as the armed conflict and the search for a better quality of life, which has 
generated a migratory process to different places in the country (44).
According to the similarity dendrogram, 69.2% of the spoligotypes were 
clustered suggesting active tuberculosis transmission, especially among the 
Wayúu, Emberá Chamí, U’wa, and Awá groups. The use of spoligotyping as 
the sole genotyping method results in low discriminatory power; therefore, 
the frequency of transmission was most likely overestimated. However, the 
spoligotyping discrimination index in this study (0.963) should be considered 
because it indicates discrimination between unrelated isolates, which was 
close to 1.0, i.e., higher (28). 
Although one of the limitations of this study was the low number of isolates 
analyzed, it is the first at the national level to characterize a large number of 
isolates from Colombian indigenous populations and the first approach to M. 
tuberculosis circulating genotypes. Our results provide partial evidence of 
the actual situation of tuberculosis among Colombian indigenous peoples, 
which can serve decision-makers in taking actions aimed at putting an end to 
the tuberculosis epidemic as set out in WHO global guidelines for 2035 (2). 
However, molecular analyses should be done using MIRU-VNTR or Whole 
Genome Sequencing methodologies to increase the discriminatory power and 
provide insights into the actual situation of tuberculosis transmission among 
indigenous peoples in Colombia.
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Supplementary table 1. Distribution of orphan patterns identified by spoligotyping in the study
Spoligotype Binary Spoligotype Octal n %
Orphan 1*
Orphan 2*
Orphan 3*
Orphan 4
Orphan 5
Orphan 6
Orphan 7
Orphan 8
Orphan 9
Orphan 10
Orphan 11
Orphan 12
Orphan 13
Orphan 14
Orphan 15
Orphan 16
Orphan 17
Orphan 18
Orphan 19
Orphan 20
Orphan 21
Orphan 22
Orphan 23
Orphan 24
Orphan 25
Orphan 26
Orphan 27
Orphan 28
Orphan 29
Orphan 30
Orphan 31
Orphan 32
Orphan 33
Orphan 34
Orphan 35
Orphan 36
Orphan 37
Orphan 38
Orphan 39
Orphan 40
Orphan 41
Orphan 42
Orphan 43
Orphan 44
Orphan 45
Orphan 46
Orphan 47
Orphan 48
Orphan 49
Orphan 50
Orphan 51
Orphan 52
Orphan 53
Orphan 54
777777775020731
577777607560731
777777775020730
677737607740331
777777774000731
776377777740731
737777777740731
777767601760771
776767607760671
777757607760731
777777604000071
777757606760731
613777777720771
777707774020621
775347606540661
774037607760771
740000000760771
777777674020721
757747636740661
776367603740721
777767600000061
777775607760771
777736777740771
577777604160731
677737607760761
777777674020731
776301703740731
776347670000731
776377771000731
776077600000171
777660007760771
777737607740771
776163607760731
777777607560730
777767607560731
277737607760770
777577607760770
677577607760771
740120000760771
074337607760700
777767634020731
357767607760771
777737775020731
577777604160771
417727607740661
077777607760411
677777600760671
677737407760771
776367770000731
776376370000731
677767607760700
777737607760671
557347775020721
777765607760661
9
3
3
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3.85
1.28
1.28
0.85
0.85
0.85
0.85
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
0.43
94
Puerto D, Erazo LM, Zabaleta A, et al. Biomédica 2019;39(Supl.2):78-92
Supplementary figure 1. Similarity 
dendrogram using the spoligotyping 
methodology
